Paper7533451
Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.
Kaplan SA and 4 others. Urology, 1995. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Papers, record 7533451. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7533451
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Hyperplasia | Major topic |
| Adult | |
| Age Factors | |
| Aged | |
| Aged, 80 and over | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Racial Groups | |
| Severity of Illness Index | |
| Single-Blind Method | |
| Urodynamics |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 26847294 | Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study. | Yonsei Med J | 2016 | https://conductscience.org/library/papers/26847294 | PubMed |
| 17516689 | Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. | Clin Drug Investig | 2004 | https://conductscience.org/library/papers/17516689 | PubMed |
| 16986060 | Factors in Predicting Failure with Medical Therapy for BPH. | Rev Urol | 2005 | https://conductscience.org/library/papers/16986060 | PubMed |
| 16985889 | alpha-Blocker Therapy: Current Update. | Rev Urol | 2005 | https://conductscience.org/library/papers/16985889 | PubMed |
| 16175413 | Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. | World J Urol | 2005 | https://conductscience.org/library/papers/16175413 | PubMed |
| 12882719 | Urethral stents in benign prostate hyperplasia. | Curr Urol Rep | 2003 | https://conductscience.org/library/papers/12882719 | PubMed |
| 12084322 | The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia. | Curr Urol Rep | 2000 | https://conductscience.org/library/papers/12084322 | PubMed |
| 9951948 | Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. | Drugs | 1999 | https://conductscience.org/library/papers/9951948 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7533451
GET https://conductscience.org/api/papers/v1/7533451/authors